Profile data is unavailable for this security.
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
- Revenue in USD (TTM)63.53m
- Net income in USD-160.93m
- Incorporated2007
- Employees181.00
- LocationFate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
- Phone+1 (858) 875-1803
- Fax+1 (302) 636-5454
- Websitehttps://fatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adaptive Biotechnologies Corp | 170.28m | -225.25m | 443.58m | 709.00 | -- | 1.42 | -- | 2.61 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Biomea Fusion Inc | 0.00 | -127.27m | 444.71m | 103.00 | -- | -- | -- | -- | -3.57 | -3.57 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -43.29 | -- | -- | -- |
Annexon Inc | 0.00 | -134.24m | 444.77m | 71.00 | -- | 1.53 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Cartesian Therapeutics Inc | 26.00m | -219.71m | 455.58m | 38.00 | -- | -- | -- | 17.52 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Theravance Biopharma Inc | 57.42m | -55.19m | 459.38m | 99.00 | -- | 2.14 | -- | 8.00 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
PepGen Inc | 0.00 | -78.63m | 459.94m | 64.00 | -- | 3.12 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Fate Therapeutics Inc | 63.53m | -160.93m | 462.10m | 181.00 | -- | 1.09 | -- | 7.27 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 20.76m | -132.49m | 462.37m | 145.00 | -- | 1.66 | -- | 22.28 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Editas Medicine Inc | 78.12m | -153.22m | 466.27m | 265.00 | -- | 1.33 | -- | 5.97 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Neurogene Inc | 0.00 | -36.32m | 471.27m | 91.00 | -- | 2.53 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Third Harmonic Bio Inc | 0.00 | -30.82m | 476.36m | 30.00 | -- | 1.74 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Travere Therapeutics Inc | 145.24m | -376.33m | 476.44m | 380.00 | -- | 2.35 | -- | 3.28 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Voyager Therapeutics Inc | 250.01m | 132.33m | 479.16m | 162.00 | 2.98 | 1.64 | 3.50 | 1.92 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Taysha Gene Therapies Inc | 15.45m | -111.57m | 480.64m | 52.00 | -- | 6.41 | -- | 31.11 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Fulcrum Therapeutics Inc | 2.81m | -97.34m | 481.69m | 76.00 | -- | 2.04 | -- | 171.73 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 21 Mar 2024 | 13.18m | 13.28% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 9.22m | 9.29% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 7.45m | 7.51% |
Point72 Asset Management LPas of 26 Jan 2024 | 4.95m | 4.98% |
Bellevue Asset Management AGas of 31 Dec 2023 | 4.85m | 4.89% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 3.58m | 3.61% |
Citadel Advisors LLCas of 31 Dec 2023 | 2.66m | 2.68% |
Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 2.62m | 2.64% |
Assenagon Asset Management SA (Germany)as of 31 Mar 2024 | 2.55m | 2.57% |
Acadian Asset Management LLCas of 31 Dec 2023 | 2.28m | 2.30% |